PRESS RELEASE published on 07/04/2025 at 07:00, 1 year 3 months ago Inside Information / Other news releases Innate Pharma discloses number of shares and voting rights as of July 3, 2025, in accordance with French regulations. Total shares: 92,183,523. Total voting rights: 92,962,943 (theoretical) and 92,944,368 (exercisable) Voting Rights Shares French Regulations Financial Disclosure Innate Pharma
BRIEF published on 06/17/2025 at 07:05, 1 year 4 months ago Innate Pharma to Participate in Key Investor Conferences Biotechnology Investor Conferences Healthcare Immunotherapy Innate Pharma
BRIEF published on 06/17/2025 at 07:05, 1 year 4 months ago Innate Pharma participera à des conférences d'investisseurs clés Biotechnologie Immunothérapie Soins De Santé Conférences D'investisseurs Innate Pharma
PRESS RELEASE published on 06/17/2025 at 07:00, 1 year 4 months ago Inside Information / Other news releases Innate Pharma to participate in H.C. Wainwright and Wolfe Research healthcare conferences showcasing their innovative immunotherapy approaches. Global biotech company expanding portfolio Biotechnology Immunotherapy Clinical-stage Innate Pharma Healthcare Conferences
BRIEF published on 06/13/2025 at 07:05, 1 year 4 months ago Innate Pharma's IPH6501 Shows Potential in Lymphoma Treatment Innate Pharma Preclinical Results IPH6501 Lymphoma R-CHOP
BRIEF published on 06/13/2025 at 07:05, 1 year 4 months ago L'IPH6501 d'Innate Pharma montre un potentiel dans le traitement du lymphome Innate Pharma Résultats Précliniques IPH6501 R-CHOP Lymphome
PRESS RELEASE published on 06/13/2025 at 07:00, 1 year 4 months ago Inside Information / Other news releases Innate Pharma highlights preclinical antitumor activity of IPH6501 in DLBCL and FL at the 2025 EHA Congress, presenting potent efficacy in in vitro and in vivo models with R-CHOP combination Preclinical Data EHA Congress Innate Pharma Antitumor Activity IPH6501
BRIEF published on 05/13/2025 at 07:05, 1 year 5 months ago Innate Pharma publie ses résultats du premier trimestre 2025 Résultats Financiers Essais Cliniques Innate Pharma Investissement Sanofi Lacutamab FDA
BRIEF published on 05/13/2025 at 07:05, 1 year 5 months ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 5 months ago Informations privilégiées / Communiqué sur comptes, résultats Innate Pharma annonce ses résultats financiers du premier trimestre 2025 et les avancées de son portefeuille, incluant des investissements et des études cliniques. Une conférence téléphonique est prévue à 14h00 CEST Résultats Financiers Conférence Téléphonique Portefeuille Études Cliniques Innate Pharma
Published on 10/28/2026 at 12:30, 4 hours 16 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 4 hours 16 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 4 hours 16 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 4 hours 16 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/28/2026 at 12:15, 4 hours 31 minutes ago BULGOLD Expands Strategic Exploration Position Around the Lutila Gold Project with Two New Exploration Licences
Published on 10/28/2026 at 15:19, 1 hour 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: Vesuvius PLC
Published on 10/28/2026 at 15:18, 1 hour 27 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle PLC
Published on 10/28/2026 at 15:18, 1 hour 27 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Published on 10/28/2026 at 15:17, 1 hour 29 minutes ago Form 8.3 - The Vanguard Group, Inc.: Segro PLC
Published on 10/28/2026 at 08:00, 8 hours 45 minutes ago Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 8 hours 45 minutes ago Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 22 hours 46 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 22 hours 46 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
